AOL

EBGLYSS for eczema: What to know about the newly FDA-approved drug from Eli Lilly

A newly approved drug for the treatment of atopic dermatitis could make a big difference to people with moderate-to-severe eczema. Image credit: Sascha Lotz/picture alliance via Getty Images. The ...
WebMD

Ebglyss: FDA Approves Once-Every-8-Week Maintenance Injection Option for Moderate to Severe Eczema in Adults and Children Ages 12 Years and Older

What Is It, and Why Does It Matter? Ebglyss (lebrikizumab-lbkz) is a prescription biologic medicine given as an under-the-skin (subcutaneous) injection to treat moderate to severe atopic dermatitis, ...

FDA approves Lilly's EBGLYSS® (lebrikizumab-lbkz) for one maintenance dose every eight weeks in patients with moderate-to-severe atopic dermatitis

Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) approved a regimen of one maintenance dose every eight weeks of a single injection (250 mg/2 mL) of ...
zacks

Lilly Gets FDA Approval for Eczema Drug Ebglyss

Eli Lilly and Company (LLY Quick Quote LLY - Free Report) announced that the FDA has granted approval to its IL-13 inhibitor Ebglyss (lebrikizumab) for treating moderate-to-severe atopic dermatitis, ...
Yahoo Finance

Eli Lilly Wins FDA Nod for Extended Ebglyss Dosing in Eczema Care

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
AOL

Eli Lilly Scores FDA Approval For Eczema Treatment Ebglyss

Friday, the FDA approved Eli Lilly And Co’s (NYSE:LLY) Ebglyss (lebrikizumab-lbkz), a targeted IL-13 inhibitor, for adults and children 12 years of age and older who weigh at least 88 pounds (40 kg) ...
Nasdaq

FDA Approval of EBGLYSS Boosts Eli Lilly’s (NYSE:LLY) Eczema Treatment Portfolio

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration (FDA) had approved its atopic dermatitis (eczema) drug, EBGLYSS (lebrikizumab-lbkz). This drug will be used for the ...
Healio

FDA approves bimonthly dosing regimen for Ebglyss in adults, children with eczema

The FDA approved a regimen of one maintenance dose every 8 weeks for lebrikizumab-lbkz in adults and children aged 12 years and older who weigh at least 88 pounds with moderate to severe atopic ...
Seeking Alpha

Lilly says once-monthly eczema injectable delivered durable disease control

Eli Lilly (LLY) announced late-stage trial data for Ebglyss, its FDA-approved therapy for atopic dermatitis (eczema), on Friday, indicating that the once-monthly injectable led to a durable treatment ...
Revolt on MSN

Kelly Rowland opens up about Destiny's Child's boldness at a young age, how eczema affected her confidence, and her love for storytelling

In this exclusive interview, Kelly Rowland talks about Destiny's Child's boldness, eczema, and her love for the storytelling ...
MarketWatch

Lilly's Ebglyss(R) for moderate-to-severe atopic dermatitis (eczema) listed on Quebec's public drug formulary

The MarketWatch News Department was not involved in the creation of this content. TORONTO, Sept. 25, 2025 /CNW/ - Today, Eli Lilly Canada Inc.'s ("Lilly") Ebglyss(R) (lebrikizumab) to treat ...